ReviewCancer letters2017
Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy.
Review in Cancer letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 177 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
177 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- A novel oncolytic peptide synergizing with immunotherapy.Oncoimmunology · 2026Article
- Identification of Four Compounds with S-RBD-Binding and Pseudovirus Entry-Inhibitory Activity.International journal of molecular sciences · 2026Article
- Mechanisms of In Vitro Cytotoxicity of Honeybee Venom Components and Melittin-Functionalized FeMaterials (Basel, Switzerland) · 2026Article
- Integrated Venomics Profiling of Apis dorsata and Vespa sp. Venoms Reveal Putative Bioactive Candidates.Chemistry & biodiversity · 2026Article
- Venom-Derived Enzyme Inhibitors as Anticancer Agents: Structure-Activity Relationships, Molecular Targets and Mechanistic Insights.Molecules (Basel, Switzerland) · 2026Review
- Article
- Animal Venoms Targeting Cellular Mechanisms: Advances and Implications for Drug Discovery and Disease Therapy.Toxins · 2026Review
- In Vitro Antitumor Effects of Melittin Attached to FeMolecules (Basel, Switzerland) · 2026Article
- From a membrane-lytic toxin to a programmable therapeutic module: exposure control and detoxified delivery strategies for translating melittin into antitumor therapy.Molecular biology reports · 2026Review
- Integrated isothermal shift assay and multi-omics identify melittin as a novel EGFR-targeting peptide to suppress NSCLC.Journal of translational medicine · 2026Article
- Targeting oral squamous cell carcinoma with venom peptides: mechanisms, selectivity and translational potential.The protein journal · 2026Review
- From Toxin to Therapy: Biomedical Applications of Bee Venom in Cancer, Diabetes, and Neurodegenerative Disorders.International journal of molecular sciences · 2026Review
- Melittin enhances PD-L1 blockade in prostate cancer by inhibiting M2 macrophage polarization and recruitment.World journal of surgical oncology · 2026Article
- Therapeutic potential of infrared-treated bee venom: enhanced multi-faceted bioactivity via compositional modulation.Bioresources and bioprocessing · 2026Article
- Redox-Responsive Polymeric Nanocapsules for Enhanced Tumor-Targeted Delivery of Antimicrobial Peptides.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Concentration-Dependent Anticancer Effects of Melittin-Functionalized Nanomaterials.Materials (Basel, Switzerland) · 2026Review
- Melittin Acts as a Radiosensitizer for Non-Small Cell Lung Cancer by Inhibiting the DNA Damage Repair System and Inducing Apoptosis.Yonsei medical journal · 2026Article
- FcIgG-GE11-Melittin as a novel EGFR targeted peptibody with potent cytotoxic activity against cancer cells.Scientific reports · 2026Article
- α-Helical Peptides Encoded in Collagen Exhibit Antimicrobial Activity with Low Cytotoxicity.Journal of natural products · 2026Article
117 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Melittin (MEL), a major peptide component of bee venom, is an attractive candidate for cancer therapy. This agent has shown a variety of anti-cancer effects in preclinical cell culture and animal model systems. Despite a convincing efficacy data against variety of cancers, its applicability to humans has met with challenges due to several issues including its non-specific cytotoxicity, degradation and hemolytic activity. Several optimization approaches including utilization of nanoparticle based delivery of MEL have been utilized to circumvent the issues. Here, we summarize the current understanding of the anticancer effects of bee venom and MEL on different kinds of cancers. Further, we also present the available information for the possible mechanism of action of bee venom and/or MEL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.